Salvage chemotherapy for lymphoma with VP-16, ifosfamide, and cisplatin

C. R. Nichols, Patrick Loehrer, A. Greist, P. S. Kubilis, R. Hoffman

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Between 1983 and 1985, we conducted a phase II clinical trial using VP-16, ifosfamide, and cisplatin (VIP) in patients with refractory lymphoma. Twenty-eight patients with bidimensional measurable disease were treated with VP-16 (75 mg/m2), ifosfamide (1.2 g/m2), and cisplatin (20 mg/m2) as daily intravenous infusions for 5 consectuve days. N-Acetylcystein, 2 g orally every 6 h, was given as a uroepithelial protective agent. All patients had received extensive combination chemotherapy prior to beginning VIP (median number of regimens = 2). Of the 25 patients evaluable for response, 2 patients achieved complete remission and 7 achieved partial remission for an overall objective response rate of 36%. The length of responses ranged from 2 months to 13 months. The predominant toxicity of VIP was myelosuppression. Of 23 patients receiving more than one course of VIP, 17 (73%) had dose reductions or delays related to poor hematologic tolerance of therapy. Uroepithelial and renal toxicity were mild. VIP demonstrates therapeutic activity in refractory lymphoma and appears comparable to other ifosfamide/VP-16 based salvage regimens.

Original languageEnglish
Pages (from-to)12-16
Number of pages5
JournalMedical and Pediatric Oncology
Volume16
Issue number1
StatePublished - 1988

Fingerprint

Ifosfamide
Etoposide
Cisplatin
Lymphoma
Drug Therapy
Protective Agents
Phase II Clinical Trials
Combination Drug Therapy
Intravenous Infusions
Kidney
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pediatrics, Perinatology, and Child Health

Cite this

Nichols, C. R., Loehrer, P., Greist, A., Kubilis, P. S., & Hoffman, R. (1988). Salvage chemotherapy for lymphoma with VP-16, ifosfamide, and cisplatin. Medical and Pediatric Oncology, 16(1), 12-16.

Salvage chemotherapy for lymphoma with VP-16, ifosfamide, and cisplatin. / Nichols, C. R.; Loehrer, Patrick; Greist, A.; Kubilis, P. S.; Hoffman, R.

In: Medical and Pediatric Oncology, Vol. 16, No. 1, 1988, p. 12-16.

Research output: Contribution to journalArticle

Nichols, CR, Loehrer, P, Greist, A, Kubilis, PS & Hoffman, R 1988, 'Salvage chemotherapy for lymphoma with VP-16, ifosfamide, and cisplatin', Medical and Pediatric Oncology, vol. 16, no. 1, pp. 12-16.
Nichols, C. R. ; Loehrer, Patrick ; Greist, A. ; Kubilis, P. S. ; Hoffman, R. / Salvage chemotherapy for lymphoma with VP-16, ifosfamide, and cisplatin. In: Medical and Pediatric Oncology. 1988 ; Vol. 16, No. 1. pp. 12-16.
@article{ebc600291ed14a9f93f5505e9e954a8a,
title = "Salvage chemotherapy for lymphoma with VP-16, ifosfamide, and cisplatin",
abstract = "Between 1983 and 1985, we conducted a phase II clinical trial using VP-16, ifosfamide, and cisplatin (VIP) in patients with refractory lymphoma. Twenty-eight patients with bidimensional measurable disease were treated with VP-16 (75 mg/m2), ifosfamide (1.2 g/m2), and cisplatin (20 mg/m2) as daily intravenous infusions for 5 consectuve days. N-Acetylcystein, 2 g orally every 6 h, was given as a uroepithelial protective agent. All patients had received extensive combination chemotherapy prior to beginning VIP (median number of regimens = 2). Of the 25 patients evaluable for response, 2 patients achieved complete remission and 7 achieved partial remission for an overall objective response rate of 36{\%}. The length of responses ranged from 2 months to 13 months. The predominant toxicity of VIP was myelosuppression. Of 23 patients receiving more than one course of VIP, 17 (73{\%}) had dose reductions or delays related to poor hematologic tolerance of therapy. Uroepithelial and renal toxicity were mild. VIP demonstrates therapeutic activity in refractory lymphoma and appears comparable to other ifosfamide/VP-16 based salvage regimens.",
author = "Nichols, {C. R.} and Patrick Loehrer and A. Greist and Kubilis, {P. S.} and R. Hoffman",
year = "1988",
language = "English",
volume = "16",
pages = "12--16",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Salvage chemotherapy for lymphoma with VP-16, ifosfamide, and cisplatin

AU - Nichols, C. R.

AU - Loehrer, Patrick

AU - Greist, A.

AU - Kubilis, P. S.

AU - Hoffman, R.

PY - 1988

Y1 - 1988

N2 - Between 1983 and 1985, we conducted a phase II clinical trial using VP-16, ifosfamide, and cisplatin (VIP) in patients with refractory lymphoma. Twenty-eight patients with bidimensional measurable disease were treated with VP-16 (75 mg/m2), ifosfamide (1.2 g/m2), and cisplatin (20 mg/m2) as daily intravenous infusions for 5 consectuve days. N-Acetylcystein, 2 g orally every 6 h, was given as a uroepithelial protective agent. All patients had received extensive combination chemotherapy prior to beginning VIP (median number of regimens = 2). Of the 25 patients evaluable for response, 2 patients achieved complete remission and 7 achieved partial remission for an overall objective response rate of 36%. The length of responses ranged from 2 months to 13 months. The predominant toxicity of VIP was myelosuppression. Of 23 patients receiving more than one course of VIP, 17 (73%) had dose reductions or delays related to poor hematologic tolerance of therapy. Uroepithelial and renal toxicity were mild. VIP demonstrates therapeutic activity in refractory lymphoma and appears comparable to other ifosfamide/VP-16 based salvage regimens.

AB - Between 1983 and 1985, we conducted a phase II clinical trial using VP-16, ifosfamide, and cisplatin (VIP) in patients with refractory lymphoma. Twenty-eight patients with bidimensional measurable disease were treated with VP-16 (75 mg/m2), ifosfamide (1.2 g/m2), and cisplatin (20 mg/m2) as daily intravenous infusions for 5 consectuve days. N-Acetylcystein, 2 g orally every 6 h, was given as a uroepithelial protective agent. All patients had received extensive combination chemotherapy prior to beginning VIP (median number of regimens = 2). Of the 25 patients evaluable for response, 2 patients achieved complete remission and 7 achieved partial remission for an overall objective response rate of 36%. The length of responses ranged from 2 months to 13 months. The predominant toxicity of VIP was myelosuppression. Of 23 patients receiving more than one course of VIP, 17 (73%) had dose reductions or delays related to poor hematologic tolerance of therapy. Uroepithelial and renal toxicity were mild. VIP demonstrates therapeutic activity in refractory lymphoma and appears comparable to other ifosfamide/VP-16 based salvage regimens.

UR - http://www.scopus.com/inward/record.url?scp=0023846136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023846136&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 12

EP - 16

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 1

ER -